# EDGAR Filing Document

**Accession Number:** 0001679082
**File Stem:** 9999999997-23-000448
**Filing Date:** 2023-2
**Character Count:** 2166
**Document Hash:** 638ecd31f2f601f97b837ccbfe41d44f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999997-23-000448.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 9999999997-23-000448

**CONFORMED SUBMISSION TYPE**: CT ORDER

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230202

**ACTION DATE**: 20230203

**RECEIVED DATE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Myovant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001679082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** CT ORDER
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89732
- **FILM NUMBER:** 23583387

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB
- **BUSINESS PHONE:** 44 207-400-3351

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB

### Attached PDF Documents

**Attachment 1:** `filename1`

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 3, 2023

# ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934

Myovant Sciences Ltd.
File No. 005-89732 - CTR#3363

Myovant Sciences Ltd. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from Exhibits (c)(4), (c)(5), (c)(6), (c)(7), (c)(8), (c)(9) and (c)(10) to an amended Schedule 13E-3 filed on January 23, 2023.

Based on representations by Myovant Sciences Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public:

Exhibits (c)(4), (c)(5), (c)(6), (c)(7), (c)(8), (c)(9) and (c)(10)

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Ted Yu
Associate Director
Division of Corporation Finance